undamentalytics Newsletter
Sign in

Biofrontera Inc. (BFRI) stock

Add to watchlist

Add holding +

NASDAQ: BFRI Nasdaq Pharmaceuticals Next results ~November 11, 2026

C+ Fundamentals grade

Biofrontera Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: free cash flow after stock pay is not positive.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Biofrontera Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds13 adding, 4 cuttingOf 2 active managers that changed their stake, 2 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Biofrontera files

Where Biofrontera stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $46m, up 17.8% on a year earlier, faster than the 13.7% growth a quarter earlier. Free-cash-flow margin rose to -17.2% from -24.0% a year earlier. Operating margin widened to -14.2% from -41.6%. It passes 2 of our 2 financial-health checks.

Our model value for Biofrontera is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 11, 2026 (estimated)

Biofrontera Inc.'s trailing-twelve-month revenue grew 17.8% year on year, with a free-cash-flow margin of -17.2%. Where it stands out: change in growth rate of +4.1pp ranks 15 of 74 pharmaceuticals companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 15.6% while net income grew 61.6%: a 46pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 17.8% over the last 12 months, against a median of 10.0% for pharmaceuticals companies we cover.
  • Growth speeding up. The growth rate is 4.1 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 27.4 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.
  • Estimates rising. Analysts' consensus for next year's earnings per share has risen 34.4% over 90 days.

Things to watch

  • Loss-making. Operating margin is -14.2%: costs exceed revenue.
  • Burning cash. Free cash flow was -17.2% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 81% and a beta of 1.6 against the S&P 500.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
-$0.05 against an average estimate of -$0.04: missed by 25.0%
Revenue
$12m, up 32.9% on a year earlier
Share reaction
+4.0% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Next report
November 11, 2026; average EPS estimate -$0.11

Biofrontera's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.3%
  • 1 week+5.8%
  • 1 month-14.3%
  • This year+52.6%
  • 1 year-20.9%
  • 5 years-98.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$46.2M
Operating margin
-14.2%
Net margin
-13.8%
EPS (TTM, diluted)
$-0.54

Growth

Revenue growth
+17.8%
Change in growth rate
+4.1 pts

Cash

Free cash flow (TTM)
-$7.9M
FCF margin
-17.2%
Stock pay % of revenue
2.4%

Earnings

Last results
August 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Biofrontera Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Biofrontera Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9%: the 10-year Treasury yield (4.9%) plus a beta of 0.9 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$8.9 ~$6.9–$11 Left out: out of range vs price (10.20x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.0 ~$3.4–$14 Left out: out of range vs price (0.01x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Biofrontera Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$150.40$18.34$2.77$1.09$0.57$0.87
Market value$166m$19m$4m$6m$6m$10m
+ Net debt (− = net cash)−$25m−$17m$3m−$6m−$6m−$5m
Enterprise value$141m$2m$7m$107804−$594005$6m
Multiples
Price / sales 6.9x0.7x0.1x0.2x0.1x0.2x
Price / earnings ——————
Price / free cash flow ——————
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 11, 2026, before the open. Analysts expect revenue of $8m and EPS of −$0.11 (range −$0.11 to −$0.11) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.18 +85% $46m +11%
Next $0.43 +339% $53m +16%

Next year's EPS estimate has moved +34.4% in 90 days, across 1 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +12.5% on 90 days ago. In the last 30 days, 0 analysts raised Biofrontera Inc.'s forecast and 1 cut it.

Consensus EPS forecast Biofrontera Inc., last 90 days
−$0.20 $0.00 $0.20 $0.40 $0.60 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.16 Current fiscal year, 60 days ago: −$0.16 Current fiscal year, 30 days ago: −$0.18 Current fiscal year, 7 days ago: −$0.18 Current fiscal year, Now: −$0.18 −$0.18 Next fiscal year, 90 days ago: $0.32 Next fiscal year, 60 days ago: $0.32 Next fiscal year, 30 days ago: $0.43 Next fiscal year, 7 days ago: $0.43 Next fiscal year, Now: $0.43 $0.43

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.16$0.32
60 days ago −$0.16$0.32
30 days ago −$0.18$0.43
7 days ago −$0.18$0.43
Now −$0.18$0.43

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.04 −$0.05 −25.0%
Mar 2026 −$0.05 −$0.41 −720.0%
Dec 2025 $0.10 $0.50 +398.1%
Sept 2025 −$0.56 −$0.57 −1.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 13, 2026

No numeric guidance in Biofrontera Inc.'s latest earnings release (filed August 13, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

2 analysts, Oct 2026
Buy2100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202622
  2. Sep 202622

Counts of recommendations published by analysts covering Biofrontera Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
0.7%
of tradable shares
Days to cover
0.25
at average volume
Short interest, 1 month
−78%
to October 15, 2026
Held by institutions
21%
of shares
Held by insiders
12.0%
of shares
Employees
84
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
BFRI−88%−85%−61%−48%+53%
Industry peers (median)−49%−13%−2%+9%−14%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
BFRI25%25%42%42%46%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
BFRI−90%−86%−78%−52%−52%
S&P 500−25%−10%−8%−19%−9%

Worst fall since October 29, 2021: 100% from December 23, 2021 to May 30, 2025. Getting back needed a 46768% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.57 – $1.61
From 52-week high
−46.0%
vs 50-day average
−23.8%
vs 200-day average
−15.9%
Volatility (1 year)
81%
Beta vs S&P 500
1.62

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±11.4%
After a week
2 up, 10 down
typical move ±15.4%
After a month
6 up, 6 down
typical move ±10.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 +4.0% +0.5% +18.4% +8.8%
May 14, 2026 −16.7% −0.4% −18.9% +4.2%
March 19, 2026 +0.1% −1.7% −6.8% +25.4%
January 13, 2026 +1.8% −0.7% +25.5% −0.8%
November 13, 2025 −16.0% −1.7% −22.6% −18.9%
August 13, 2025 +3.9% +0.4% −5.4% −9.6%
May 15, 2025 −7.0% +1.1% −4.4% −5.6%
March 21, 2025 −12.5% +1.8% −21.1% −18.9%
November 13, 2024 −25.2% −0.6% −17.2% +12.5%
August 14, 2024 −5.7% +2.0% −1.6% +4.9%
May 15, 2024 −15.5% +1.0% −11.6% −15.9%
March 15, 2024 −28.0% −0.1% −31.4% +3.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Biofrontera Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Biofrontera Inc.
$30M $35M $40M $45M $50M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $33.6M Revenue (TTM), FY23 Q4: $34.1M Revenue (TTM), FY24 Q1: $33.3M Revenue (TTM), FY24 Q2: $35.2M Revenue (TTM), FY24 Q3: $35.4M Revenue (TTM), FY24 Q4: $37.3M Revenue (TTM), FY25 Q1: $38M Revenue (TTM), FY25 Q2: $39.2M Revenue (TTM), FY25 Q3: $37.2M Revenue (TTM), FY25 Q4: $41.7M Revenue (TTM), FY26 Q1: $43.2M Revenue (TTM), FY26 Q2: $46.2M $46.2M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $33.6M
FY23 Q4 $34.1M
FY24 Q1 $33.3M
FY24 Q2 $35.2M
FY24 Q3 $35.4M
FY24 Q4 $37.3M
FY25 Q1 $38M
FY25 Q2 $39.2M
FY25 Q3 $37.2M
FY25 Q4 $41.7M
FY26 Q1 $43.2M
FY26 Q2 $46.2M
Revenue growth, TTM YoY Biofrontera Inc.
0% 10% 20% 30% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 21.4% Revenue growth, TTM YoY, FY23 Q4: 18.8% Revenue growth, TTM YoY, FY24 Q1: 20.2% Revenue growth, TTM YoY, FY24 Q2: 21.3% Revenue growth, TTM YoY, FY24 Q3: 5.2% Revenue growth, TTM YoY, FY24 Q4: 9.5% Revenue growth, TTM YoY, FY25 Q1: 14.3% Revenue growth, TTM YoY, FY25 Q2: 11.2% Revenue growth, TTM YoY, FY25 Q3: 5.1% Revenue growth, TTM YoY, FY25 Q4: 11.7% Revenue growth, TTM YoY, FY26 Q1: 13.7% Revenue growth, TTM YoY, FY26 Q2: 17.8% 17.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 21.4%
FY23 Q4 18.8%
FY24 Q1 20.2%
FY24 Q2 21.3%
FY24 Q3 5.2%
FY24 Q4 9.5%
FY25 Q1 14.3%
FY25 Q2 11.2%
FY25 Q3 5.1%
FY25 Q4 11.7%
FY26 Q1 13.7%
FY26 Q2 17.8%
Operating margin (TTM) Biofrontera Inc.
-80% -60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -72.7% Operating margin (TTM), FY23 Q4: -66.6% Operating margin (TTM), FY24 Q1: -68.1% Operating margin (TTM), FY24 Q2: -54.0% Operating margin (TTM), FY24 Q3: -54.8% Operating margin (TTM), FY24 Q4: -46.1% Operating margin (TTM), FY25 Q1: -42.9% Operating margin (TTM), FY25 Q2: -41.6% Operating margin (TTM), FY25 Q3: -47.4% Operating margin (TTM), FY25 Q4: -27.2% Operating margin (TTM), FY26 Q1: -25.7% Operating margin (TTM), FY26 Q2: -14.2% -14.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -72.7%
FY23 Q4 -66.6%
FY24 Q1 -68.1%
FY24 Q2 -54.0%
FY24 Q3 -54.8%
FY24 Q4 -46.1%
FY25 Q1 -42.9%
FY25 Q2 -41.6%
FY25 Q3 -47.4%
FY25 Q4 -27.2%
FY26 Q1 -25.7%
FY26 Q2 -14.2%
FCF margin (TTM) Biofrontera Inc.
-80% -60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -72.3% FCF margin (TTM), FY23 Q4: -73.1% FCF margin (TTM), FY24 Q1: -73.9% FCF margin (TTM), FY24 Q2: -53.7% FCF margin (TTM), FY24 Q3: -51.2% FCF margin (TTM), FY24 Q4: -27.5% FCF margin (TTM), FY25 Q1: -29.0% FCF margin (TTM), FY25 Q2: -24.0% FCF margin (TTM), FY25 Q3: -32.3% FCF margin (TTM), FY25 Q4: -32.0% FCF margin (TTM), FY26 Q1: -21.6% FCF margin (TTM), FY26 Q2: -17.2% -17.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -72.3%
FY23 Q4 -73.1%
FY24 Q1 -73.9%
FY24 Q2 -53.7%
FY24 Q3 -51.2%
FY24 Q4 -27.5%
FY25 Q1 -29.0%
FY25 Q2 -24.0%
FY25 Q3 -32.3%
FY25 Q4 -32.0%
FY26 Q1 -21.6%
FY26 Q2 -17.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 19 24 29 34 37 42 46
EBITDA −9 −25 −18 −22 −17 −11 −6
Operating income −10 −25 −19 −23 −17 −11 −7
Net income −11 −38 −1 −20 −18 −11 −6
Diluted EPS −$3835.84 −$34.24 −$0.61 −$13.02 −$3.22 −$1.04 −$0.54
Growth (year on year)
Revenue — +27.9% +19.0% +18.8% +9.5% +11.7% +17.8%
Margins
EBITDA margin −50.2% −104.1% −64.4% −64.8% −45.0% −26.9% −13.9%
Operating margin −51.0% −104.6% −64.8% −66.6% −46.1% −27.2% −14.2%
Net margin −58.3% −156.5% −2.2% −59.1% −47.6% −25.3% −13.8%
Free-cash-flow margin — — −56.6% −73.1% −27.5% −32.0% −17.2%
Cash flow
Cash from operations −12 −27 −16 −25 −10 −13 −8
Capital spending — — 0 0 0 0 0
Free cash flow — — −16 −25 −10 −13 −8
Stock-based pay — 0 2 1 1 1 1
Free cash flow after stock pay — — −18 −26 −11 −14 −9
Balance sheet
Cash 8 25 17 1 6 6 5
Total debt 0 0 0 4 0 0 0
Net debt (negative = net cash) −8 −25 −17 3 −6 −6 −5
Diluted shares 3m 1m 1m 2m 6m 10m 12m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $24m
Short-term assets $12mLonger-term assets $12m
What it owes, and who funded it · $24m
Short-term liabilities $11mLonger-term liabilities $8mShareholders' equity $6m
  • Short-term assets cover short-term liabilities $12m of assets due within a year against $11m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $12m short-term assets against $8m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Biofrontera Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
6.5%
of revenue
Sales & admin spending
84.9%
of revenue
Days sales outstanding
44 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated BFRI CPIX AQST IMCC BGM AYTU Median
Revenue, last 12 months $46m $40m $54m $39m $38m $58m $276m
Revenue growth, last 12 months 17.8% −5.2% 22.6% −0.7% 51.1% −13.3% 9.9%
Revenue growth, 3-year average 16.7% −0.6% 5.2% — — −18.8% 5.5%
Revenue growth, latest quarter 32.9% −18.8% 38.1% — — 6.4% 6.5%
Gross margin — 82.9% 67.0% 17.7% 16.6% 64.0% 62.0%
Operating margin −14.2% −24.1% −97.5% −21.2% −33.2% −14.4% −5.9%
Operating margin, 3-year average −36.6% −19.0% −80.9% — — −9.6% −7.4%
Net margin −13.8% −27.4% −144.6% −20.7% −52.6% −24.8% −7.3%
Cash from operations / revenue −17.2% 1.9% −83.9% 8.6% −6.3% 5.7% 10.2%
Free-cash-flow margin −17.2% 1.7% −85.0% 8.6% −10.4% 5.6% 8.6%
Free-cash-flow margin, 3-year average −31.6% 5.4% −80.3% — — 5.8% 7.4%
Stock pay / revenue 2.4% 1.1% 17.3% 0.0% 27.0% 1.2% 3.6%
Change in share count — 1.5% 27.4% 71.3% >999% 52.9% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth 17.8% 10.0% 25 of 74
Change in growth rate Growth +4.1pp -0.3pp 15 of 74
Operating margin Profitability -14.2% -5.9% 38 of 67
Net margin Profitability -13.8% -7.3% 45 of 75
Free-cash-flow margin Cash generation -17.2% 10.1% 57 of 74
Stock pay as % of revenue Cash generation 2.4% 3.6% 31 of 69
Days sales outstanding Balance sheet 44 days 72 days 13 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$2.6M
Institutions reporting
19
Shares held vs prior quarter
▲ 15.4%
Positions opened / closed
9 / 2

Top buyers and sellers, Q2 2026: 13 institutions bought and 4 sold ; the biggest buyer was Renaissance Technologies LLC (+158K shares) and the biggest seller Aigh Capital Management LLC (−175K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Rosalind Advisors, Inc. $1.2M 1.3M 46.2% ▲ 9.6%
Aigh Capital Management LLC $699,585 740K 26.8% ▼ 19.2%
Renaissance Technologies LLC $148,921 158K 5.7% New
Citadel Advisors LLC $99,222 105K 3.8% New
Jane Street Group, LLC $87,932 93K 3.4% New
Geode Capital Management, LLC $72,513 77K 2.8% ▼ 29.8%
Vanguard Capital Management LLC $67,525 71K 2.6% ▲ 36.6%
Vanguard Fiduciary Trust Co $58,365 62K 2.2% 0.0%
Xtx Topco Ltd $49,066 52K 1.9% ▲ 130.7%
HRT Financial LP $40,000 43K 1.5% New
Northern Trust Corp $29,817 32K 1.1% New
UBS Group AG $17,518 19K 0.7% ▲ 1102.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Biofrontera Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 30, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • May 14, 2026
  • March 19, 2026
  • January 13, 2026
  • November 13, 2025
  • August 13, 2025

Recent SEC filings

Data status

When each part of this page on Biofrontera Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Biofrontera Inc. in brief

What does Biofrontera Inc. do?
Biofrontera Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Biofrontera Inc.'s stock ticker?
Biofrontera Inc. trades under the ticker BFRI on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Biofrontera Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Biofrontera Inc. reported revenue of $46.2M, 17.8% higher than a year earlier, according to its SEC filings.
What is Biofrontera Inc.'s free cash flow?
Biofrontera Inc.'s free-cash-flow margin is -17.2% of revenue over the trailing twelve months, ranking 57 of the 74 pharmaceuticals companies we cover.
Who are Biofrontera Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Rosalind Advisors, Inc., Aigh Capital Management LLC and Renaissance Technologies LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Biofrontera Inc.'s market cap?
On November 2, 2026, Biofrontera Inc.'s market capitalisation was about $10.2M and net debt of -$4.7M. Market figures come from third-party market data and may be delayed.
Who are Biofrontera Inc.'s competitors?
In our Pharmaceuticals peer group, the companies closest to Biofrontera Inc. are Cumberland Pharmaceuticals Inc, Aquestive Therapeutics, Inc., IM Cannabis Corp., BGM Group Ltd. and Aytu Biopharma, Inc. The side-by-side comparison below sets their revenue, margins and growth against Biofrontera Inc.'s.
When is Biofrontera Inc.'s next earnings date?
Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Biofrontera Inc. announces its own schedule.